Developing Leads to Shorten Duration of TB Chemotherapy
One of the major goals of tuberculosis (TB) research programs is to shorten the TB treatment period. After the introduction of rifampicin and pyrazinamide in the 1970s, it was possible to develop a six-month treatment regimen and the current standard chemotherapy includes a two-month intensive phase (four-drug regimen) followed by a four-month continuation phase (two-drug regimen). For patients suffering from latent or multi-drug resistant tuberculosis (MDR-TB) the treatment period is even longer and often extends to more than 18 months.
Although one of the two major TB drugs, rifampicin, is derived from a bacterial producer (actinomycete) screening campaigns at the partner sites mostly relied on chemically synthesized compounds. We now aim at exploring natural product scaffolds from microbial sources (mostly myxobacteria) that show favorable anti-Mtb activity and new MOAs, and extend our knowledge on how these molecules kill Mtb.
This multi-site project is funded by the Bill & Melinda Gates Foundation (BMGF) and involves academic and industrial partners from the USA, South Africa, the United Kingdom and Germany.
Bill and Melinda Gates Foundation
- Microbial Natural Products- Prof. Dr. Rolf Müller